Just call it the Energizer Bunny. Despite drawing fire from consumer groups, legislators and other concerned critics wanting to curb it, direct-to-consumer pharmaceutical advertising keeps on going.

The whimsical consumer campaign for Takedas insomnia drug Rozerem has generated lots of buzz, just not the kind of recognition that leads to new patient starts. That may be changing.

To offer maximum returns, pharmaceutical Web sites and CRM programs must be designed and built using the insights from the user experience, say Laura Keller and Mark McConaghy

Sometimes the best person for the job is no person at all. Julian M. Parreño looks at how non-manpowered selling solutions helped breathe new life into a 17-year-old brand: the Intal Inhaler

It was a plot point on a famous episode of Seinfeld, but that was the high point for the Today Sponge in recent years. Now, 12 years after Wyeth stopped making it, a new owner is looking to relaunch the contraceptive sponge to a highly-segmented swatch of consumers with brighter packaging, print ads and a Web site.

The FDA has agreed to permit limited use of Novartis Zelnorm (tegaserod maleate) by some patients through a restricted access program, following the drugs voluntary withdrawal over cardiovascular safety concerns earlier this year.

Strong sales of cholesterol drugs helped Schering-Plough post a twofold increase in quarterly profit this week, but earnings may expose an over-reliance on Vytorin and Zetia.

Par Pharmaceutical reached a settlement and license agreement with Ortho-McNeil Pharmaceutical, ending a patent suit related to the Johnson Johnson units Ultracet acute pain product.

Three years after the FDA yanked its Wild Thing ads off the air, Pfizer is again taking a playful approach with a Viagra TV spot riffing on the Elvis hit Viva Las Vegas. And this time they got the agencys OK in advance.

Eli Lilly posted strong second-quarter sales results yesterday, despite a 19% net income drop due to charges and other items.